Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $2.0 million.

  • Orthofix Medical's Change in Receivables rose 43130.29% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 3598.4%. This contributed to the annual value of $9.5 million for FY2024, which is 850.06% down from last year.
  • Per Orthofix Medical's latest filing, its Change in Receivables stood at $2.0 million for Q3 2025, which was up 43130.29% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Orthofix Medical's Change in Receivables registered a high of $13.3 million during Q4 2023, and its lowest value of -$5.4 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Receivables was -$259000.0 (2022), whereas its average is $1.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 114362.93% in 2023, then crashed by 273106.8% in 2025.
  • Quarter analysis of 5 years shows Orthofix Medical's Change in Receivables stood at $9.8 million in 2021, then plummeted by 30.6% to $6.8 million in 2022, then skyrocketed by 96.33% to $13.3 million in 2023, then dropped by 18.73% to $10.8 million in 2024, then tumbled by 81.92% to $2.0 million in 2025.
  • Its Change in Receivables stands at $2.0 million for Q3 2025, versus -$2.7 million for Q2 2025 and -$2.4 million for Q1 2025.